Intermolecular, Inc. Securities Litigation

If you purchased a significant amount of shares of Intermolecular, Inc. (NASDAQ: IMI), you have certain options. Investors should register for updates.


Lawsuit Overview

Defendant:Intermolecular, Inc.
Date Filed:June 6th, 2019

According to the Complaint, Intermolecular is the trusted partner for advanced materials innovation. Advanced materials are at the core of innovation for a wide range of industries including semiconductors, consumer electronics, automotive, and aerospace. The Company has a ten-year track record helping leading companies accelerate and de-risk materials innovation.

This action stems from a proposed transaction announced on May 6, 2019, pursuant to which Intermolecular, Inc. will be acquired by affiliates of Merck KGaA: EMD Group Holding II, Inc.

On May 6, 2019, Intermolecular's Board of Directors caused the Company to enter into an agreement and plan of merger with Merck. Pursuant to the terms of the Merger Agreement, Intermolecular's stockholders will receive $1.20 in cash for each share of Intermolecular common stock they own.

On May 28, 2019, Defendants filed a proxy statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Intermolecular, Inc.

First Identified Complaint

Adam Franchi, et al. v. Intermolecular, Inc., et al.

Date Filed:June 6th, 2019
Class Period Start:May 6th, 2019
Class Period End:June 6th, 2019
First Identified Complaint Filings
#Document TitleFiling Date